Who Paid My Doc
David Schneider
Allergy & Immunology Metairie, LA Medical Doctor
NPI 1275590945 CMS profile 102871
3225 Danny Park Ste 100, Metairie, LA 70002
General payments
$9,808
Research payments
$1,747
Ownership & investment interest
$0
Research they led as principal investigator
$79,588
Through program year 2025, David Schneider of Metairie, LA is reported in the CMS Open Payments database as having received $9,808 across 438 general payments and $1,747 in research payments paid to them. Separately, studies naming them as principal investigator received $79,588 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 75th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $235 | 2 | |
| 2024 | General | $145 | 1 | |
| 2024 | Research | $1,747 | 11 | |
| 2023 | General | $1,313 | 50 | |
| 2022 | General | $2,275 | 106 | |
| 2021 | General | $2,676 | 116 | |
| 2020 | General | $1,692 | 94 | |
| 2019 | General | $1,472 | 69 |
Beside peers
- David Schneider
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to David Schneider were reported at $235. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | David Schneider | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,472 | $594 | $163–$1,512 | $163 |
| 2020 | $1,692 | $426 | $106–$1,233 | $114 |
| 2021 | $2,676 | $638 | $157–$1,708 | $132 |
| 2022 | $2,275 | $790 | $205–$1,961 | $149 |
| 2023 | $1,313 | $852 | $220–$2,147 | $160 |
| 2024 | $145 | $865 | $203–$2,267 | $164 |
| 2025 | $235 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
449 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in Louisiana
David Kaufman
Allergy & Immunology · Shreveport, LA
Reena Mehta
Allergy & Immunology · New Orleans, LA
Kenneth Paris
Allergy & Immunology · New Orleans, LA
Brice Rolston
Allergy & Immunology · Covington, LA
Caroline Caperton
Allergy & Immunology · Shreveport, LA
Sonia Kamboj
Allergy & Immunology · Marrero, LA
Related records
Allergy & Immunology in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.